New recommendations suggest holding back on SGLT2 inhibitors and GLP-1s among those at a lower risk for cardiovascular or ...

No blanket recommendation can be made for SGLT2 inhibitors and GLP-1 receptor agonists in adults with type 2 diabetes (T2D) ...

Adults with type 2 diabetes who initiate SGLT2 inhibitors within 3 months of a diagnosis of a urinary tract infection have a ...

Use of SGLT2 inhibitors was significantly associated with a 58% reduced relative risk of serious renal events (a composite of renal replacement therapy [RRT], death from renal causes, and ...

EXTON, Pa., May 12, 2021 /PRNewswire/ — Nephrologists have long considered chronic kidney disease (CKD) progression and diabetic kidney disease (DKD) as areas in dire need of new and better t… ...

The SGLT2 inhibitor empagliflozin confers kidney-protective benefits and can therefore be given safely and effectively to patients when they are hospitalized for acute myocardial infarction (MI ...

Similarly, researchers identified 1,207 SGLT2 inhibitor users and 1,207 nonusers in the Geisinger cohort, of whom 2.2% and 4.6%, respectively, experienced acute kidney injury.

Use of SGLT2 inhibitors was associated with improved kidney health among a diverse multiethnic cohort of Asian adults with type 2 diabetes, researchers found in a retrospective cohort study ...

Meeting Coverage > ESC SGLT2 Inhibitor Wows in Chronic Kidney Disease — DAPA-CKD shows fewer renal events, prolonged overall survival by Crystal Phend, Senior Editor, MedPage Today August 30, 2020 ...

Bottom line of study: SGLT2 inhibitors have become a major drug used to treat diabetes, heart failure, and chronic kidney disease. However, there have been questions as to whether it is safe to ...

Sodium-glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of kidney complications in people with type 2 diabetes, researchers conclude in a new study. SGLT2 inhibitors are a class of drug ...

The changes will impact millions of people with type 2 diabetes in England in the biggest shake-up of care in a decade ...